Abstract
Acarbose is a glucosidase inhibitor which is currently being tested in clinical trials for the treatment of diabetes mellitus and hyperlipidemia. We report here preliminary observations obtained in six patients with non-insulin-dependent diabetes mellitus (NIDDM) and hyperlipemia (plasma triglyceride levels over 250 mg%), who were treated with acarbose (50–100 mg t. i. d.) for 12 weeks. The treatment protocol was a crossover, double-blind study with 4 weeks of washout period between treatments. The following biochemical parameters were measured every 2 weeks: fasting blood glucose, hemoglobin A1c, fructosamine, total cholesterol, triglyceride, and highdensity lipoprotein (HDL) cholesterol. No other antidiabetic or antilipemic drugs were taken. Some patients continued with their antihypertensive treatment (beta blockers only), as required.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Bar-On, H., Raz, I., Kidron, M. (1988). Acarbose in the Treatment of NIDDM Patients with Hyperlipidemia. In: Creutzfeldt, W. (eds) Acarbose for the Treatment of Diabetes Mellitus. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73583-7_44
Download citation
DOI: https://doi.org/10.1007/978-3-642-73583-7_44
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-19145-2
Online ISBN: 978-3-642-73583-7
eBook Packages: Springer Book Archive